{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:icosapent-ethyl",
  "owner": "cardio",
  "kind": "drug",
  "slug": "icosapent-ethyl",
  "name": "Icosapent ethyl",
  "aliases": [
    "Vascepa"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "A prescription medicine, sold as Vascepa, that is an ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. The US label lists it for lowering very high triglycerides in adults, and, added to a statin, for lowering the risk of heart attack, stroke and some other events in adults with raised triglycerides and either established cardiovascular disease or diabetes plus other risk factors. The label warns of a higher risk of atrial fibrillation or atrial flutter needing hospital care, and of bleeding.",
  "summary_technical": "RxNorm ingredient 1304974. NDA202057, with an original submission dated 2012-07-26 in the openFDA record. The evidence recorded here is the Amarin label and the FDA record only; this record reads no outcome trial.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-10-30",
  "last_evidence_check": "2026-10-30",
  "next_review_due": "2027-04-30",
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "1304974",
      "normalized_value": "1304974",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "condition-area": [
        "risk-and-prevention",
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says studies suggest that EPA reduces liver production or release of very low-density lipoprotein triglycerides and enhances triglyceride clearance from circulating VLDL particles. It says the mechanisms behind fewer cardiovascular events are not completely understood."
  },
  "content_digest": "319e7ae642de075482d2d07a486fe7995f79a4494b07e88818f113640e3fa83c",
  "review": {
    "content_digest": "319e7ae642de075482d2d07a486fe7995f79a4494b07e88818f113640e3fa83c",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-icosapent-ethyl-approval",
      "owner": "cardio",
      "subject_entity_id": "cardio:icosapent-ethyl",
      "category": "regulatory",
      "statement": "The openFDA Drugs@FDA record for NDA202057 lists Vascepa, from AMARIN PHARMS, with an original submission (ORIG 1) in status AP (approved) dated 26 July 2012.",
      "context": {
        "id": "cardio:ctx-fda-vascepa-us-label",
        "label": "Adults with raised triglycerides, as the US Vascepa label describes them",
        "recipient": "adult",
        "population": "Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.",
        "care_setting": "Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications",
        "geography": "United States (FDA label)",
        "life_stage_note": "Adults; the label states adult patients",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label text and a regulatory record)",
        "eligibility": {
          "inclusion": [],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "An openFDA record, which openFDA says is unvalidated. It gives dates as compact numbers and does not state the indication approved in 2012; the label indications above are the current ones.",
      "editorial_state": "draft",
      "checked_at": "2026-10-30",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].submissions[16]",
          "applicability_note": "Original submission in the FDA record.",
          "snapshot": {
            "id": "cardio:openfda-nda202057-2026-10-30",
            "retrieved_at": "2026-10-30T19:20:11Z",
            "content_hash": "41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-nda202057",
            "source_type": "regulator",
            "title": "FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record)",
            "canonical_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202057",
            "identifiers": [
              {
                "scheme": "fda-nda",
                "value": "NDA202057",
                "normalized_value": "NDA202057",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drugsfda record for application NDA202057 returned on 2026-10-30. It writes dates as compact numbers (YYYYMMDD).",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The raw record is committed at research/snapshots/ct-openfda-nda202057.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].sponsor_name",
          "applicability_note": "Applicant name in the FDA record.",
          "snapshot": {
            "id": "cardio:openfda-nda202057-2026-10-30",
            "retrieved_at": "2026-10-30T19:20:11Z",
            "content_hash": "41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f",
            "source_effective_date": null,
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-nda202057",
            "source_type": "regulator",
            "title": "FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record)",
            "canonical_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202057",
            "identifiers": [
              {
                "scheme": "fda-nda",
                "value": "NDA202057",
                "normalized_value": "NDA202057",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drugsfda record for application NDA202057 returned on 2026-10-30. It writes dates as compact numbers (YYYYMMDD).",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted, as the openFDA terms page states (fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The raw record is committed at research/snapshots/ct-openfda-nda202057.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "dfdc4b0fda775360a6825096cda6afaf705c833aa33b6cc301060b8e8b24d196",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-icosapent-ethyl-approval.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-icosapent-ethyl-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:icosapent-ethyl",
      "category": "descriptive",
      "statement": "The US Vascepa label says Vascepa (icosapent ethyl) is indicated, as an add-on to statin treatment at the highest dose the patient can tolerate, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (150 mg/dL or higher) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. It is also indicated, as an adjunct to diet, to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia. The label says the effect on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.",
      "context": {
        "id": "cardio:ctx-fda-vascepa-us-label",
        "label": "Adults with raised triglycerides, as the US Vascepa label describes them",
        "recipient": "adult",
        "population": "Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.",
        "care_setting": "Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications",
        "geography": "United States (FDA label)",
        "life_stage_note": "Adults; the label states adult patients",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label text and a regulatory record)",
        "eligibility": {
          "inclusion": [],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "These are indications as the label states them, in the label version dated 2026-03-23. They say what FDA has approved the medicine for, not how well it works for any person. The trial evidence behind the cardiovascular indication is not read in this atlas yet.",
      "editorial_state": "draft",
      "checked_at": "2026-10-30",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0]",
          "applicability_note": "Label indications and limitations of use.",
          "snapshot": {
            "id": "cardio:openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508-2026-10-30",
            "retrieved_at": "2026-10-30T19:20:10Z",
            "content_hash": "12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd",
            "source_effective_date": "2026-03-23",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508",
            "source_type": "label",
            "title": "Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508)",
            "canonical_url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508",
            "identifiers": [
              {
                "scheme": "spl-set-id",
                "value": "9c1a2828-1583-4414-ab22-a60480e8e508",
                "normalized_value": "9c1a2828-1583-4414-ab22-a60480e8e508",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA drug label endpoint)",
            "edition": "openFDA drug label record for the Amarin Pharma Inc. label of Vascepa, label effective 20260323, fetched 2026-10-30.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed at research/snapshots/ct-openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "5605075c9be5befddf3f431d96d799ef18bf366a9bb3bca6c99958679ec538d0",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-icosapent-ethyl-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-icosapent-ethyl-label-safety",
      "owner": "cardio",
      "subject_entity_id": "cardio:icosapent-ethyl",
      "category": "safety",
      "statement": "The US Vascepa label says Vascepa is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization, and with an increased risk of bleeding.",
      "context": {
        "id": "cardio:ctx-fda-vascepa-us-label",
        "label": "Adults with raised triglycerides, as the US Vascepa label describes them",
        "recipient": "adult",
        "population": "Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.",
        "care_setting": "Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications",
        "geography": "United States (FDA label)",
        "life_stage_note": "Adults; the label states adult patients",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label text and a regulatory record)",
        "eligibility": {
          "inclusion": [],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "Warnings as the label states them, in the label version dated 2026-03-23. The label gives event counts from one trial; this atlas does not repeat them and has not read the trial.",
      "editorial_state": "draft",
      "checked_at": "2026-10-30",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].warnings_and_cautions[0]",
          "applicability_note": "Label warnings and precautions, sections 5.1 and 5.3.",
          "snapshot": {
            "id": "cardio:openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508-2026-10-30",
            "retrieved_at": "2026-10-30T19:20:10Z",
            "content_hash": "12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd",
            "source_effective_date": "2026-03-23",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508",
            "source_type": "label",
            "title": "Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508)",
            "canonical_url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508",
            "identifiers": [
              {
                "scheme": "spl-set-id",
                "value": "9c1a2828-1583-4414-ab22-a60480e8e508",
                "normalized_value": "9c1a2828-1583-4414-ab22-a60480e8e508",
                "match": "exact",
                "version": null,
                "label": null,
                "from_source": false
              }
            ],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA drug label endpoint)",
            "edition": "openFDA drug label record for the Amarin Pharma Inc. label of Vascepa, label effective 20260323, fetched 2026-10-30.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, fetched 2026-10-30, sha256 b11f712bfb11d03319675fc04e6948133a83c57aa2913b7f18d3677d0209f723, hash only). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed at research/snapshots/ct-openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "631a224d1de786a2f86866a0512d9756e97d0536aea48388570971c223ea3799",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-icosapent-ethyl-label-safety.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "evaluated_for",
        "label": "US label: indicated to lower severe hypertriglyceridemia and, with a statin, cardiovascular risk in adults with raised triglycerides",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:hypertriglyceridemia",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-icosapent-ethyl-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Filed under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "The US label says icosapent ethyl is an ethyl ester of an omega-3 fatty acid",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:omega-3-fatty-acid-drugs",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:openfda-label-9c1a2828-1583-4414-ab22-a60480e8e508-2026-10-30",
          "locator": "results[0].description[0]"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "investigates",
        "label": "Investigated in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:ct-nct04177680",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct04177680-2022-03-04",
          "locator": "protocolSection.armsInterventionsModule.interventions[1].name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "investigates",
        "label": "Investigated in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:ct-nct04505098",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct04505098-2023-07-18",
          "locator": "protocolSection.armsInterventionsModule.interventions[0].name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "investigates",
        "label": "Investigated in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:ct-nct06466278",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct06466278-2025-10-03",
          "locator": "protocolSection.armsInterventionsModule.interventions[0].name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "investigates",
        "label": "Investigated in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:ct-nct07762755",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ctgov-nct07762755-2026-08-13",
          "locator": "protocolSection.armsInterventionsModule.interventions[0].name"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "contains",
        "label": "Contained in",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:fdaprod-nda202057",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:ofeed-nda202057-2026-03-16",
          "locator": "products[0].active_ingredients[0].name"
        },
        "primary": false,
        "role": "active",
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/icosapent-ethyl/",
  "context_path": "api/v1/context/cardio--icosapent-ethyl.md"
}
